TICKERNERD
Menu
ANABANABHealthcare · Biotechnology

ANAB Stock Forecast: AnaptysBio, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$56
−1.59% on the day

The 8 Wall Street analysts covering AnaptysBio, Inc. hold a median 12-month price target of $84 — +50.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
99 / 100
Median analyst target
$84
Analysts covering
8
Revenue$25.6M−8.0% y/y
Operating income−$34.6M
Net income−$52.9M
Free cash flow−$25.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−1.6%
YTD
+72.3%
1Y
+277.5%
From 52W high
−20.2%
From 52W low
+330.7%
$13
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANAB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AnaptysBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Issuance
97
Growth
92
Accruals
92
Momentum
83
Volatility
64
Size
38
Revisions
36

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (36): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANAB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANAB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26ANABHigh $140Median $84Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $70Median $84High $140

The green dot is the last close — the median target sits +50.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026TD CowenMaintainsBuy$75 → $70
24 Aug 2026HC Wainwright & Co.ReiteratesBuy$95
10 June 2026HC Wainwright & Co.AssumesBuy$95
13 May 2026BarclaysMaintainsOverweight—
13 May 2026UBSMaintainsBuy—
4 May 2026Piper SandlerMaintainsOverweight—
28 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026BarclaysMaintainsOverweight—
21 Apr 2026UBSMaintainsBuy—
31 Mar 2026Piper SandlerMaintainsOverweight—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026UBSMaintainsBuy—
12 Mar 2026WedbushMaintainsOutperform—
9 Mar 2026Truist SecuritiesMaintainsHold—
5 Mar 2026StifelMaintainsBuy—
4 Mar 2026BarclaysMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026BarclaysMaintainsOverweight—
7 Jan 2026UBSAssumesBuy$20 → $70
17 Dec 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANAB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANAB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, AnaptysBio, Inc. returned +277.5% against +18.5% for the S&P 500, dividends included.

ANAB vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26ANABS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANAB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−162.5%
Analysts raising
0
Analysts cutting
4
Fundamentals

AnaptysBio, Inc. (ANAB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−124.4×

Cheaper than 99% of US stocks

Price / sales
7.2×

Cheaper than 18% of US stocks

Price / book
129.6×

Cheaper than 1% of US stocks

EV / EBITDA
39.8×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
−8.0%

Higher than 17% of US stocks

Earnings growth (YoY)
−8.0%

Higher than 28% of US stocks

Gross margin
—
Operating margin
−135.5%

Higher than 12% of US stocks

Net margin
−11.5%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−114.6%

Higher than 12% of US stocks

Return on assets
6.8%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AnaptysBio, Inc. (ANAB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AnaptysBio, Inc. has a market value of $1.7B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 31 Mar 2026: $232.4M. The latest quarter shrank 8.0% year on year.

  • Net income over the same four quarters: −$26.8M, a −11.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.08.

  • Free cash flow in the twelve months to 31 Mar 2026: $4.4M, after $69K of capital spending.

  • AnaptysBio, Inc. spent $64.2M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 29.0M.

  • Trailing P/E: −124.4×; forward P/E: 10.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AnaptysBio, Inc. employs 104 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

ANAB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANABAnaptysBio, Inc.$1.7B
99
INBXInhibrx Biosciences, Inc.$1.7B
27
SEPNSepterna, Inc.$1.7B
91
NVAXNovavax, Inc.$1.7B
54
AVLNAvalyn Pharma, Inc.$1.7B
1
FBRXForte Biosciences, Inc.$1.6B
—
SNDXSyndax Pharmaceuticals, Inc.$1.7B
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AnaptysBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANAB news & analysis

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 1 Sept 2026neutral

AnaptysBio announced that chief financial officer Chris Murphy is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15, 2026, at 3:30pm ET. The company noted its financial collaborations with GSK for Jemperli and with Vanda for imsidolimab.

Why it matters — An ANAB watcher would care because a CFO presentation at a major investment conference provides an opportunity for the company to communicate with investors about its financial collaborations.

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

Zacks Investment Research · 24 Aug 2026neutral

GSK's supplemental Biologics License Application for Jemperli has been granted FDA priority review for dMMR/MSI-H rectal cancer, with a decision expected in February 2027. Separately, GSK's Hibsago received approval in Japan for chronic hepatitis B.

Why it matters — This item concerns GSK's oncology and hepatitis B pipeline developments rather than AnaptysBio, so it provides no direct indication about ANAB's outlook but signals competitive activity in the broader biopharma space.

AnaptysBio: The Royalty Waterfall Is About To Reverse

Seeking Alpha · 29 July 2026positive

AnaptysBio has repositioned as a focused royalty management company, with its value primarily tied to Jemperli royalties from GSK. The company now operates virtually with a 95% targeted EBIT margin and over $140M net cash, having eliminated its prior R&D burn.

Why it matters — ANAB watchers would care because once the Sagard obligation is paid by mid-2027, the company will retain high-margin, growing royalty streams that escalate with Jemperli sales.

FAQ

Frequently asked questions about ANAB stock

What is the ANAB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering AnaptysBio, Inc. have a median 12-month price target of $84, with estimates ranging from $70 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANAB stock a buy right now?

Of the 8 analysts covering AnaptysBio, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AnaptysBio, Inc. 99 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANAB?

As at 8 Sept 2026, AnaptysBio, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ANAB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +50.8% from the last close, and Ticker Nerd's factor model ranks AnaptysBio, Inc. 99 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANAB stock forecast for 2030?

No analyst covering AnaptysBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $140 over the next 12 months.

How has ANAB stock performed over the past year?

AnaptysBio, Inc. returned +277.5% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AnaptysBio, Inc. do?

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases.

What is the latest news on ANAB?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference". AnaptysBio announced that chief financial officer Chris Murphy is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 15, 2026, at 3:30pm ET. The company noted its financial collaborations with GSK for Jemperli and with Vanda for imsidolimab.

Company

About AnaptysBio, Inc.

AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfunction, with current work spanning clinical and preclinical candidates as well as royalty and collaboration assets. Its portfolio includes investigational therapies aimed at conditions such as rheumatoid arthritis, ulcerative colitis, atopic dermatitis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. The company also manages financial collaborations tied to partnered assets, reflecting a business model that combines internal drug development with externally partnered programs. Based in San Diego, California, AnaptysBio plays a role in the biotechnology market as a specialist in immune cell modulation and antibody therapeutics.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.anaptysbio.com